We are thrilled to see our CEO Alexander Seyf in BioPharm International’s recent publication, which focuses on the importance and acceleration of innovation within the Biopharma industry and the challenges, such as supply constraints and investment concerns, that will continue to play a role in the progression of the industry into 2025 and beyond.

Alexander highlights the recent realization of the need for biopharma industry investment in the US and discusses the increased availability of funding in the UK due to initiatives such as Innovate UK. The article continues to evidence his point that more activities such as government-incentivized R&D are supporting the industry in the EU more than we have seen before.

This commitment to funding and strategic initiatives is crucial for driving innovation and accelerating the development of advanced therapies and Autolomous is excited for what the future holds in 2025 and beyond!

Read the full article here.